Evolution of epitope-specific IgE and IgG
Allergens
/ immunology
Antigens, Plant
/ immunology
Arachis
/ immunology
Child, Preschool
Epitopes
/ immunology
Female
Humans
Immunoglobulin E
/ immunology
Immunoglobulin G
/ immunology
Immunomodulation
Infant
Male
Membrane Proteins
/ immunology
Peanut Hypersensitivity
/ immunology
Plant Proteins
/ immunology
IgE
IgG(4)
Peanut allergy
antibody
bead-based epitope assay
biomarkers
sequential epitope
Journal
The Journal of allergy and clinical immunology
ISSN: 1097-6825
Titre abrégé: J Allergy Clin Immunol
Pays: United States
ID NLM: 1275002
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
30
07
2020
revised:
15
12
2020
accepted:
15
01
2021
pubmed:
17
2
2021
medline:
11
11
2021
entrez:
16
2
2021
Statut:
ppublish
Résumé
In the LEAP (Learning Early About Peanut Allergy) trial, early consumption of peanut in high-risk infants was found to decrease the rate of peanut allergy at 5 years of age. Sequential epitope-specific (ses-)IgE is a promising biomarker of clinical peanut reactivity. We sought to compare the evolution of ses-IgE and ses-IgG Sera from 341 children (LEAP cohort) were assayed at baseline, 1, 2.5, and 5 years of age, with allergy status determined by oral food challenge at 5 years. A bead-based epitope assay was used to quantitate ses-IgE and ses-IgG In children avoiding peanut who became peanut allergic, the bulk of peanut ses-IgE did not develop until after 2.5 years. Minimal increases of ses-IgE occurred after 1 year in consumers, but not to the same epitopes as those in children developing peanut allergy. No major changes in ses-IgE were seen in nonallergic or sensitized children. IgE in sensitized consumers was detected against peanut proteins. ses-IgG Early peanut consumption in infants at high risk of developing peanut allergy appears to divert the immunologic response to a presumably "protective" effect. In general, consumers tend to generate ses-IgG
Sections du résumé
BACKGROUND
In the LEAP (Learning Early About Peanut Allergy) trial, early consumption of peanut in high-risk infants was found to decrease the rate of peanut allergy at 5 years of age. Sequential epitope-specific (ses-)IgE is a promising biomarker of clinical peanut reactivity.
OBJECTIVE
We sought to compare the evolution of ses-IgE and ses-IgG
METHODS
Sera from 341 children (LEAP cohort) were assayed at baseline, 1, 2.5, and 5 years of age, with allergy status determined by oral food challenge at 5 years. A bead-based epitope assay was used to quantitate ses-IgE and ses-IgG
RESULTS
In children avoiding peanut who became peanut allergic, the bulk of peanut ses-IgE did not develop until after 2.5 years. Minimal increases of ses-IgE occurred after 1 year in consumers, but not to the same epitopes as those in children developing peanut allergy. No major changes in ses-IgE were seen in nonallergic or sensitized children. IgE in sensitized consumers was detected against peanut proteins. ses-IgG
CONCLUSIONS
Early peanut consumption in infants at high risk of developing peanut allergy appears to divert the immunologic response to a presumably "protective" effect. In general, consumers tend to generate ses-IgG
Identifiants
pubmed: 33592205
pii: S0091-6749(21)00216-5
doi: 10.1016/j.jaci.2021.01.030
pmc: PMC8480440
mid: NIHMS1684849
pii:
doi:
Substances chimiques
Allergens
0
Antigens, Plant
0
Ara h 1 protein, Arachis hypogaea
0
Ara h 3 allergen, Arachis hypogea
0
Epitopes
0
Immunoglobulin G
0
Membrane Proteins
0
Plant Proteins
0
Immunoglobulin E
37341-29-0
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
835-842Subventions
Organisme : NIAID NIH HHS
ID : N01AI15416
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272200800029C
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI109565
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM062754
Pays : United States
Organisme : NIAID NIH HHS
ID : UM2 AI117870
Pays : United States
Informations de copyright
Copyright © 2021 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Références
J Allergy Clin Immunol. 2015 May;135(5):1249-56
pubmed: 25670011
Clin Exp Allergy. 2015 Feb;45(2):471-84
pubmed: 25213872
J Allergy Clin Immunol. 2016 Oct;138(4):1108-1118
pubmed: 27297994
J Allergy Clin Immunol. 2003 Jul;112(1):202-7
pubmed: 12847500
N Engl J Med. 2015 Feb 26;372(9):803-13
pubmed: 25705822
Mol Immunol. 2012 Jul;51(3-4):337-46
pubmed: 22555070
Sci Rep. 2019 Dec 5;9(1):18425
pubmed: 31804555
N Engl J Med. 2016 Apr 14;374(15):1435-43
pubmed: 26942922
J Allergy Clin Immunol. 2004 Apr;113(4):776-82
pubmed: 15100687
J Allergy Clin Immunol. 2008 Mar;121(3):737-743.e10
pubmed: 18234310
J Allergy Clin Immunol. 2018 Apr;141(4):1343-1353
pubmed: 29097103
J Allergy Clin Immunol. 2005 Oct;116(4):893-9
pubmed: 16210066
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792